GH Research PLC (NASDAQ:GHRS - Get Free Report) shares reached a new 52-week high during trading on Monday . The company traded as high as $20.50 and last traded at $19.12, with a volume of 4225029 shares traded. The stock had previously closed at $10.60.
Wall Street Analyst Weigh In
GHRS has been the topic of a number of research reports. Canaccord Genuity Group dropped their price objective on GH Research from $31.00 to $28.00 and set a "buy" rating on the stock in a research note on Monday, November 18th. HC Wainwright reissued a "buy" rating and issued a $40.00 price objective on shares of GH Research in a research note on Monday, January 27th.
Check Out Our Latest Stock Analysis on GHRS
GH Research Trading Up 2.7 %
The firm has a market capitalization of $722.18 million, a price-to-earnings ratio of -17.57 and a beta of 0.93. The stock has a fifty day moving average of $9.03 and a 200-day moving average of $9.05.
Hedge Funds Weigh In On GH Research
A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its holdings in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 1.3% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,686,689 shares of the company's stock after buying an additional 85,000 shares during the quarter. RA Capital Management L.P. owned 12.85% of GH Research worth $44,734,000 as of its most recent filing with the Securities and Exchange Commission. 56.90% of the stock is currently owned by institutional investors and hedge funds.
GH Research Company Profile
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
Read More
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
